Ayşegül Doğan1,2, Selami Demirci3,4, Dilek Telci3, Serli Canikyan5, Merve Kongur6, Bülent Dede7, Fikrettin Şahin3. 1. Genetics and Bioengineering Department, Faculty of Engineering, Yeditepe University, Kayisdagi, Istanbul, Turkey. aguldgn@gmail.com. 2. National Cancer Instıtute, CDBL, NIH, Frederick, MD, USA. aguldgn@gmail.com. 3. Genetics and Bioengineering Department, Faculty of Engineering, Yeditepe University, Kayisdagi, Istanbul, Turkey. 4. National Heart, Lung and Blood Institute (NHLBI), NIH, Bethesda, MD, USA. 5. Onkim Stem Cell Technologies, Istanbul, Turkey. 6. Acıbadem Labcell, Stem Cell Laboratory and Umbilical Cord Blood Bank, Istanbul, Turkey. 7. Department of Chemistry, Faculty of Sciences and Arts, Süleyman Demirel University, Isparta, Turkey.
Abstract
PURPOSE: Renal cell carcinoma (RCC) accounts for approximately 80% of the primary renal cancers, and current treatment strategies are not sufficient to provide a certain solution. Since there are not many treatment options, interest in discovery of alternative drugs has increased. METHODS: In the current study, anticancer activity of a novel heterodinuclear Cu(II)-Mn(II) complex (Schiff base-SB) in combination with poly(ethylene oxide) and poly(propylene oxide) block copolymer (pluronic) P85 was tested against RCC. Cell viability, apoptosis and gene expression analysis were conducted in vitro by using Renca cells. RESULTS: The results revealed that the SB-P85 combination decreased cell proliferation by increasing the apoptotic gene expressions and apoptosis. Renca-injected BALB/c mice were used to mimic early stage of RCC model. Treatment with SB-P85 combination suppressed tumor formation and growth compared to baseline. CONCLUSION: Overall, SB-P85 showed promising anticancer activity against RCC in vitro and in vivo.
PURPOSE:Renal cell carcinoma (RCC) accounts for approximately 80% of the primary renal cancers, and current treatment strategies are not sufficient to provide a certain solution. Since there are not many treatment options, interest in discovery of alternative drugs has increased. METHODS: In the current study, anticancer activity of a novel heterodinuclear Cu(II)-Mn(II) complex (Schiff base-SB) in combination with poly(ethylene oxide) and poly(propylene oxide) block copolymer (pluronic) P85 was tested against RCC. Cell viability, apoptosis and gene expression analysis were conducted in vitro by using Renca cells. RESULTS: The results revealed that the SB-P85 combination decreased cell proliferation by increasing the apoptotic gene expressions and apoptosis. Renca-injected BALB/c mice were used to mimic early stage of RCC model. Treatment with SB-P85 combination suppressed tumor formation and growth compared to baseline. CONCLUSION: Overall, SB-P85 showed promising anticancer activity against RCC in vitro and in vivo.
Entities:
Keywords:
Chemotherapy; P85; Pluronic; Renal cell carcinoma; Schiff base
Authors: Bernard Escudier; Tim Eisen; Walter M Stadler; Cezary Szczylik; Stéphane Oudard; Michael Siebels; Sylvie Negrier; Christine Chevreau; Ewa Solska; Apurva A Desai; Frédéric Rolland; Tomasz Demkow; Thomas E Hutson; Martin Gore; Scott Freeman; Brian Schwartz; Minghua Shan; Ronit Simantov; Ronald M Bukowski Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Ayşegül Doğan; Mehmet E Yalvaç; Fikrettin Şahin; Alexander V Kabanov; András Palotás; Albert A Rizvanov Journal: Int J Nanomedicine Date: 2012-09-10
Authors: Rasha H Al-Serwi; Gamal Othman; Mohammed A Attia; Eman T Enan; Mohamed El-Sherbiny; Seham Mahmoud; Nehal Elsherbiny Journal: Molecules Date: 2020-10-14 Impact factor: 4.411